Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
Department of Nephrology and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea.
J Am Soc Nephrol. 2021 Aug;32(8):1987-2004. doi: 10.1681/ASN.2020091373. Epub 2021 Jun 16.
Peripheral vascular diseases may induce chronic ischemia and cellular injury distal to the arterial obstruction. Cellular senescence involves proliferation arrest in response to stress, which can damage neighboring cells. Renal artery stenosis (RAS) induces stenotic-kidney dysfunction and injury, but whether these arise from cellular senescenceand their temporal pattern remain unknown.
Chronic renal ischemia was induced in transgenic INK-ATTAC and wild type C57BL/6 mice by unilateral RAS, and kidney function ( micro-MRI) and tissue damage were assessed. Mouse healthy and stenotic kidneys were analyzed using unbiased single-cell RNA-sequencing. To demonstrate translational relevance, cellular senescence was studied in human stenotic kidneys.
Using intraperitoneal AP20187 injections starting 1, 2, or 4 weeks after RAS, selective clearance of cells highly expressing p16 attenuated cellular senescence and improved stenotic-kidney function; however, starting treatment immediately after RAS induction was unsuccessful. Broader clearance of senescent cells, using the oral senolytic combination dasatinib and quercetin, in C57BL/6 RAS mice was more effective in clearing cells positive for p21 () and alleviating renal dysfunction and damage. Unbiased, single-cell RNA sequencing in freshly dissociated cells from healthy and stenotic mouse kidneys identified stenotic-kidney epithelial cells undergoing both mesenchymal transition and senescence. As in mice, injured human stenotic kidneys exhibited cellular senescence, suggesting this process is conserved.
Maladaptive tubular cell senescence, involving upregulated p16 (), p19 (), and p21 () expression, is associated with renal dysfunction and injury in chronic ischemia. These findings support development of senolytic strategies to delay chronic ischemic renal injury.
外周血管疾病可导致动脉阻塞远端的慢性缺血和细胞损伤。细胞衰老涉及到对压力的增殖抑制,这可能会损伤邻近的细胞。肾动脉狭窄(RAS)可导致狭窄肾脏功能障碍和损伤,但这些是否来自于细胞衰老以及它们的时间模式尚不清楚。
通过单侧 RAS 诱导 INK-ATTAC 转基因和野生型 C57BL/6 小鼠的慢性肾缺血,并评估肾功能(微 MRI)和组织损伤。使用无偏单细胞 RNA 测序分析小鼠健康和狭窄的肾脏。为了证明转化相关性,研究了人类狭窄肾脏中的细胞衰老。
使用腹腔注射 AP20187,在 RAS 后 1、2 或 4 周开始,选择性清除高度表达 p16 的细胞可减轻细胞衰老并改善狭窄肾脏的功能;然而,在 RAS 诱导后立即开始治疗是不成功的。使用口服 Senolytic 组合 dasatinib 和槲皮素更有效地清除 C57BL/6 RAS 小鼠中 p21 阳性的衰老细胞(),并缓解肾功能障碍和损伤。从健康和狭窄的小鼠肾脏中新鲜分离的细胞进行无偏单细胞 RNA 测序,鉴定出经历间充质转化和衰老的狭窄肾脏上皮细胞。与在小鼠中一样,受损的人类狭窄肾脏表现出细胞衰老,表明该过程是保守的。
适应性肾小管细胞衰老,涉及上调的 p16 ()、p19 () 和 p21 () 表达,与慢性缺血中的肾功能障碍和损伤有关。这些发现支持开发 Senolytic 策略来延迟慢性缺血性肾损伤。